Another success story:
Successful recovery of COVID-19 pneumonia in a patient from Colombia after receiving chloroquine and clarithromycin.
Millán-Oñate J1,2, Millan W3, Mendoza LA3, Sánchez CG3, Fernandez-Suarez H4, Bonilla-Aldana DK2,5,6, Rodríguez-Morales AJ7,8,9.
Author information
Abstract
BACKGROUND:
COVID-19 pandemics is a challenge for public health and infectious diseases clinicians, especially for the therapeutical approach that is not yet adequately defined. Amid this situation, investigational agents are being used, including chloroquine. We report here the clinical features and therapeutic course of the first reported patient with confirmed COVID-19 pneumonia that recovered in Colombia, after the use of chloroquine and clarithromycin.
CASE PRESENTATION:
A 34-year-old male, returning from Spain, presented with complaints of fever, and cough, and class-II obesity, being hospitalized. The respiratory viruses and bacteria tested by FilmArray® PCR were negative. Two days later, clarithromycin was started because the patient was suspected as community-acquired pneumonia. At the third day, the rRT-PCR confirmed the SARS-CoV-2 infection. A day later, chloroquine was started because of that. His chest computed tomography was performed and showed bilateral multifocal ground-glass opacities with consolidation, which suggested viral pneumonia as a differential diagnosis. Progressively his clinical condition improved and at day 9, patient rRT-PCR for SARS-CoV-2 became negative. The patient was discharged and isolated at home per 14 days.
CONCLUSIONS:
Our patient improved significantly. This and other COVID-19 cases are urgently demanding results from clinical trials that support evidence-based therapeutical approaches to this pandemic and the clinical management of patients, especially those at critical care
https://ann-clinmicrob.biomedcentral.com/articles/10.1186/s12941-020-00358-y
heard a talking head complain he never saw dosages or treatment plans mentioned, so from your link, breaking out the plan, that you study authors:
March 3 - [patient] began self-medication with acetaminophen
March 6 admission: Treatment with ampicillin/sulbactam (intravenous 3 g q4h) and clarithromycin (intravenous 500 mg q12h) was initiated. We treated the patient with oxygen inhalation, antibiotics, and nutritional support. a temperature of 38.4 °C and cephalea, both solved with acetaminophen
March 7 - day 2 - At the second day patient also received oseltamivir (orally 75 mg q12h).
Mar 8 - day 3 - oxygen and pharm agents continued
Mar 9 - day 4 - At the fourth day, it was decided to add chloroquine, phosphate, to the treatment (orally 300 mg, base, q12h) per 10 days plus continuing oseltamivir and antibiotics. continuing with febrile episodes, treated with acetaminophen.
Mar 10 - day 5 - no requirements of supplemental oxygen. [anxiety treated with] trazodone (orally 50 mg)
Mar 11 - day 6 - some dyspnea walking to bathroom. [but walking]
Mar 12 - day 7 - clinical condition had improved, with no fever, no dyspnea, no thrombocytopenia, with normal arterial-blood gases and improvement of the C-reactive protein levels, but remaining with leukopenia and lymphopenia
Mar 13 - day 8 - At this day, chloroquine and oseltamivir were discontinued after completed 5 days of treatment. the leukopenia improved, heart rate 90, bp 120/80, respiratory rate 20, temp 36.2, PO2 94%.
Mar 14 - day 9 - Discharged to 14 day home quarantine. leukocyte counts normal, mild elevation of the C-reactive protein. no fever nor cough. rRT-PCR negative.